Telecom Italia backs its full-year guidance after posting higher revenue
By Najat Kantouar
Telecom Italia (IT:TIT) (UK:0H6I) (TIIAY) has confirmed its guidance for the year after posting higher revenue for the first quarter.
The Italian telecommunications company said late Wednesday that earnings before interest, taxes, depreciation, and amortization after leases at March 31 came to 1.2 billion euros ($1.30 billion), up 3% on year.
Earnings before interest, taxes, depreciation, and amortization-a closely watched metric for profitability-were EUR1.5 billion, up 1.6% on an on-year basis.
Group revenue rose to EUR3.9 billion from EUR3.8 billion, up 1.2% on-year. Service revenue increased to EUR3.7 billion driven by growth in both its domestic business and Brazil.
For the year, Telecom Italia continues to expect group revenue to increase by 3% to 4% and by 2% to 3% for TIM Domestic. Organic Ebitda after leases is still expected to grow by 8% to 9% and 9% to 10% for TIM Domestic.
Write to Najat Kantouar at najat.kantouar@wsj.com
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-30-24 0527ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks